Prediction: Pfizer Stock Could Double by 2031

Pfizer (NYSE:PFE) is currently trading at $25.62, offering a 6.7% annual dividend yield. Despite beating earnings estimates for five consecutive quarters before a stumble in Q1 2026, the stock is up only 6.37% year-to-date. Could Pfizer shares double to $50 by 2031?

Rating Change

No specific analyst rating change is mentioned in the article, but the prediction implies a potential upside based on fundamentals.

Analyst Rationale

The prediction is based on several factors:

• High dividend yield (6.7%) attracting income-focused investors.
• Strong track record of beating earnings estimates for five straight quarters.
• Stock trading at relatively low levels compared to book value.
• Potential growth from the pipeline of new drugs.

Context

Despite positive earnings performance, the stock has remained nearly flat over the past month, with a slight decline of 0.23%. It has also underperformed the broader healthcare sector year-to-date.

What to Make of It

The potential for Pfizer stock to double by 2031 hinges on the company's ability to sustain earnings growth and achieve breakthroughs in its drug pipeline. Investors are advised to evaluate risks and potential returns based on their own financial situation.